Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
13
×
clinical trials
13
×
life sciences
national blog main
novartis
13
×
san francisco blog main
13
×
san francisco top stories
boston blog main
national top stories
boston top stories
national
raleigh-durham blog main
raleigh-durham top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
amgen
cancer
gene therapy
immunotherapy
startups
biogen
cancer immunotherapy
gilead sciences
glaxosmithkline
What
roundup
bio
drug
drugs
ipo
new
news
approval
available
biofourmis
biological
biologics
biotech
blood
cancer
can’t
cells
clears
convenience
days
devices
digestive
enzymes
fda
head
help
humans
hurdle
medicines
nash
patients
pill
proteins
public
rani’s
robotic
survive
swallowing
that’s
therapies
Language
unset
Current search:
biotech
×
novartis
×
" clinical trials "
×
" san francisco blog main "
×
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Rani’s “Robotic Pill” for Biologics Clears First Hurdle in Humans
@xconomy.com
5 years ago
Rani’s “Robotic Pill” for Biologics Clears First Hurdle in Humans
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines